Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO

$DBTX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $DBTX alert in real time by email

BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced approval of its Clinical Trial Application (CTA) by the Spanish Agency of Medicines and Medical Devices (AEMPS) to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate. DB-OTO is being developed in collaboration with Regeneron Pharmaceuticals, Inc. and is a cell-selective, adeno-associated virus (AAV) gene therapy product candidate designed to provide durable, physiological hearing in individuals with profound, congenital hearing loss caused by mutations of the otoferlin gene.

The CTA in Spain is part of an international regulatory strategy for clinical development of DB-OTO, which also includes a regulatory clearance for an Investigational New Drug (IND) application in the United States in October 2022 and a CTA approval by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) in January 2023. Decibel expects that clinical trial participants in the U.K. and Spain will be infants two years of age and younger. The Company anticipates reporting the initial safety and tolerability data and preliminary efficacy data, as measured by ABR, from the first patients in the Phase 1/2 clinical trial in the first quarter of 2024.

"Spain is an important country within our DB-OTO clinical development strategy, and our trial will leverage the collaborations and natural history work that we have pursued there over the past several years," said Laurence Reid, Ph.D., Chief Executive Officer at Decibel. "Our team believes that DB-OTO could be a transformative treatment for individuals with otoferlin-related hearing loss, and this approval broadens the opportunity to evaluate its potential in infants two years of age and younger."

The Phase 1/2 dose escalation clinical trial, known as CHORD™, is designed to evaluate the safety, tolerability and efficacy of DB-OTO in pediatric patients with congenital hearing loss due to an otoferlin deficiency. In addition to safety and tolerability endpoints, the auditory brainstem response (ABR) -- an objective, clinically accepted, physiologic measure of hearing sensitivity -- will be used as an efficacy endpoint in the clinical trial. The ABR, which was used to characterize dose-response of DB-OTO after intra-cochlear delivery in translational studies in animal models, provides an opportunity to rapidly assess hearing functionality and sensitivity.

DB-OTO received Orphan Drug and Rare Pediatric Disease designations from the U.S. Food and Drug Administration in 2021 and was granted European Orphan Drug status by the European Medicines Agency (EMA) Committee on Orphan Medicinal Products (COMP) in March 2023.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel's pipeline, including its lead gene therapy product candidate, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of creating a world of connection for people with hearing and balance disorders. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow us on Twitter.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Decibel's strategy, future operations, prospects, plans, objectives of management, the therapeutic potential for Decibel's product candidates and preclinical programs, the potential benefits of cell-selective expression, the design of the Phase 1/2 clinical trial of DB-OTO and the expected timelines for initiating a Phase 1/2 clinical trial of DB-OTO and announcing data from the trial constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Decibel may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the timing of and Decibel's ability to obtain approval to initiate clinical development of its program candidates, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, whether Decibel's cash resources are sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements, uncertainties related to the impact of the COVID-19 pandemic on Decibel's business and operations, as well as the risks and uncertainties identified in Decibel's filings with the Securities and Exchange Commission (SEC), including those risks detailed under the caption "Risk Factors" in Decibel's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in other filings Decibel may make with the SEC. In addition, the forward-looking statements included in this press release represent Decibel's views as of the date of this press release. Decibel anticipates that subsequent events and developments will cause its views to change. However, while Decibel may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Decibel's views as of any date subsequent to the date of this press release.

Investor Contact:

Julie Seidel

Stern IR, Inc.

212-362-1200

Julie.seidel@sternir.com

Media Contact:

Chris Railey

Ten Bridge Communications

617-834-0936

chris@tenbridgecommunications.com



Primary Logo

Get the next $DBTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DBTX

DatePrice TargetRatingAnalyst
3/15/2023$7.00 → $2.00Outperform → Market Perform
SVB Securities
12/2/2021$25.00Buy
JonesTrading
11/15/2021$23.00Buy
HC Wainwright & Co.
11/10/2021$15.00 → $14.00Outperform
SVB Leerink
10/22/2021$21.00Outperform
Robert W. Baird
10/22/2021$21.00Outperform
Baird
More analyst ratings

$DBTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Lifshitz Law PLLC Announces Investigations of WMC, MITT, DBTX, and CTG

    NEW YORK, Aug. 12, 2023 (GLOBE NEWSWIRE) -- Western Asset Mortgage Capital Corporation (NYSE:WMC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of WMC to AG Mortgage Investment Trust, Inc. Under the terms of the proposed merger, WMC shareholders will receive 1.5 shares of AG Mortgage Investment Trust, Inc. for each share of WMC common stocked owned and a cash payment from Angelo Gordon equal to approximately 9.99% of the aggregate per share merger consideration (not to exceed $7 million in total). If you are a WMC investor, and would like additional information about our investigation, please complete the Information R

    $CTG
    $DBTX
    $MITT
    $WMC
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update

    - Activated CHORDTM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities; anticipate dosing first patient in the Phase 1/2 clinical trial in the second half of 2023 - - Received FDA Breakthrough Therapy Designation for DB-020 for protection against hearing loss associated with cisplatin chemotherapy - - Announced on August 9 definitive agreement for Regeneron Pharmaceuticals to acquire Decibel - BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financi

    $DBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs

    Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel's lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Decibel Therapeutics, Inc. (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a definitive agreement for the acquisition of

    $DBTX
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$DBTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$DBTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$DBTX
SEC Filings

See more

$DBTX
Leadership Updates

Live Leadership Updates

See more
  • Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

    - Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO - - Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for CHORD to expand the Phase 1/2 clinical trial to the U.K. and Spain in patients two years of age and younger - - Initiated manufacturing activities to support IND-enabling studies for our AAV.103 product candidate designed to restore hearing in individuals with mutations in the GJB2 gene - BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing

    $DBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors

    BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Matthew Kapusta to its Board of Directors. "We are pleased to welcome Matt to the Decibel Board. He is an accomplished life sciences executive who has played a key role in advancing gene therapy products from the laboratory to patients in need," said Laurence Reid, Ph.D., Chief Executive Officer at Decibel. "Matt's appointment to the Board provides us with a critical strategic perspective, as we continue to build Decibel and lead

    $DBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

    - Received clearance from US FDA for IND and from UK MHRA for CTA to initiate CHORD™, a global Phase 1/2 dose escalation clinical trial of DB-OTO in pediatric patients - - Plan to initiate the CHORD™ trial in the First Half of 2023 - - Presented key non-clinical data at the 46th Annual ARO MidWinter Meeting supporting compelling safety profile of DB-OTO and preclinical data supporting selection of AAV.103 product candidate - BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial result

    $DBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$DBTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more